Recent Updates
Recently added Catalysts

Cell-based Trivalent Split Influenza Virus Vaccine

Phase 1

Seasonal Influenza | Vaccine | Infectious Disease |Sinovac Biotech, Ltd|Trials Updated: Oct 22, 2026

Cell-based Trivalent Split Influenza Virus Vaccine target and mechanism

ModalityVaccine

Also known as Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment175

FDA Designations

No designations recorded

Cell-based Trivalent Split Influenza Virus Vaccine clinical trials

Cell-based Trivalent Split Influenza Virus Vaccine · 1 trial · 1 indication

Phase 1 1
NCT07889193Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)Seasonal Influenza
NOT YET_RECRUITING175 Analytics
PHASE1NOT YET_RECRUITING
Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)
Seasonal Influenza
NCT07889193175
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of adverse reactions
0-28 days after each dose

Incidence of adverse reactions from Day 0 to Day 28 after each dose

Secondary Endpoints

Incidence of adverse reactions
0-7 days after each dose
Incidence of serious adverse events(SAEs)
From the first dose up to 6 months after the last dose
Incidence of abnormal and clinically significant hematology, serum biochemistry and urinalysis parameters on Day 3 after vaccination
Day 3 after vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Investigational Group :Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)EXPERIMENTALChildren aged 6-35 months and vaccine-naïve children aged 3-8 years: 2 doses administered 28 days apart. All other participants: 1 single dose
Active Comparator Group: Egg-based Trivalent Split Influenza Virus Vaccine (eTIV)ACTIVE_COMPARATORChildren aged 6-35 months and vaccine-naïve children aged 3-8 years: 2 doses administered 28 days apart. All other participants: 1 single dose
Placebo Group: PlaceboPLACEBO_COMPARATORChildren aged 6-35 months and vaccine-naïve children aged 3-8 years: 2 doses administered 28 days apart. All other participants: 1 single dose

Interventions

NameTypeDescription
Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)BIOLOGICALInvestigational trivalent split influenza virus vaccine produced in MDCK cells, administered intramuscularly.
Egg-based Trivalent Split Influenza Virus Vaccine (eTIV)BIOLOGICALLicensed trivalent split influenza virus vaccine (Anflu) produced in embryonated chicken eggs, administered intramuscularly.
PlaceboOTHER0.9% normal saline for intramuscular injection.
Unlock Study Design Details

Eligibility Criteria

Age Range6 Months to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy trial participants aged ≥6 months; Among them, for children aged 3-8 years: * Influenza vaccine-naïve: children who have never received any influenza vaccine (licensed or investigational); * Previously vaccinated: children who have received at least 1 dose o...

Countries:China
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 22, 2026NCT07889193NEW_TRIAL: changed
LOWOct 22, 2026NCT07889193NEW_TRIAL: changed

Explore more on BiopharmaWatch

Sinovac Biotech, Ltd (SVA)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with CCompanies A to ZEvery biotech and pharma company we track